The Study of Ω-NaBen, a Novel Crystalline Form of Sodium Benzoate, Has Been Published in CNS & Neurological Disorders - Drug Targets, Indicating Its Superior Physicochemical Properties, Central Nervous System Effects, and Antipsychotic Activities.
“Ω-NaBen exemplifies a novel molecular entity much improves the biophysicochemical properties of the sodium benzoate.” Dr. Guochuan Emil Tsai said.
Press Release
March 18, 2025
Los Angeles, California, March 18, 2025
A recent study by SyneuRx has revealed superior pharmaceutical properties of Ω(omega)-NaBen, a novel crystalline form of sodium benzoate (NaBen). Ω-NaBen is the last alphabet of Greek. Ω-NaBen reflects the ultimate supreme value of the Nostradamus compound he first discovered and purified in 1556.
In the study, Ω-NaBen can therapeutically improve all three major symptom domains of schizophrenia model, including positive, negative, and cognitive symptoms. Ω-NaBen also shows enhanced aqueous solubility and therefore improves the bioavailability and antipsychotic effects. In addition, Ω-NaBen also has much better crystal-stability either by itself or combined clozapine. The findings of Ω-NaBen have been published in the peer-reviewed journal, CNS & Neurological Disorders – Drug Targets.
NaBen can increases the synaptic D-serine level to enhance NMDA receptor-mediated neurotransmission and therapeutically improve the symptoms of schizophrenia and cognition and memory of dementia. Nevertheless, the therapeutic effect is not dose-efficient due to the low bioavailability, therefore requires large unrealistic dosages. To improve NaBen, SyneuRx have discovered all crystalline forms of NaBen. Among them, Ω-NaBen exhibits exceptional bioavailability and therapeutic effects in the preclinical study. A multi-center clinical study (ClinicalTrials.gov Identifier: NCT03094429) is currently ongoing for assessing the safety and efficacy of Ω-NaBen as an add-on therapy with clozapine in refractory schizophrenia. Once developed successfully, the combination of clozapine and Ω-NaBen, a novel and superior crystalline NaBen, can work as a therapy beyond the last line treatment of schizophrenia—clozapine therapy.
Professor Dr. Guochuan Emil Tsai from UCLA, highlighted, “Ω-NaBen exemplifies an effective strategy for the patients with schizophrenia and taking the last line of treatment, clozapine; it extend the frontier of the treatment of schizophrenia.”